Patents by Inventor Yayoi Kawato
Yayoi Kawato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230085282Abstract: A technique for predicting the presence or absence of an aroma property or an olfactory receptor activation property in a substance is provided. The presence or absence of the objective property is predicted for a test substance on the basis of the maximum similarity of stereochemical structure between the test substance and a reference substance.Type: ApplicationFiled: September 30, 2022Publication date: March 16, 2023Applicant: AJINOMOTO CO., INC.Inventors: Yusuke IHARA, Chiori IJICHI, Yayoi KAWATO, Yasuko SOMEKAWA, Takatsugu HIROKAWA
-
Publication number: 20230028073Abstract: An agent containing at least one aroma compound selected from the group consisting of E-beta-damascone, S-(2-methyl-3-furyl)ethanethioate, beta-caryophyllene oxide, beta-ionone, 2,5-dihydroxy-1,4-dithiane, methyl anthranilate, S-furfuryl thioformate, 1-isothiocyanate-3-(methylthio)propane, nootkatone, 1,4-dioxacycloheptadecane-5,17-dione, sclareol, and sclareolide is effective for masking an unpleasant smell and for making oral products in which an unpleasant smell is masked.Type: ApplicationFiled: September 22, 2022Publication date: January 26, 2023Applicant: AJINOMOTO CO., INC.Inventors: Yuji NAKADA, Yayoi KAWATO, Shingo SUGIYAMA, Seiji KITAJIMA, Chiori IJICHI
-
Publication number: 20210239714Abstract: Measuring the amount of lipocalin 15 in an olfactory mucosa sample or an olfactory mucus sample taken from a mammal is useful for non-subjectively and objectively diagnosing olfactory sense and is easily applied to clinical practice.Type: ApplicationFiled: April 22, 2021Publication date: August 5, 2021Applicant: Ajinomoto Co., Inc.Inventors: Chiori IJICHI, Kenji KONDO, Ayaka SHIRASAWA, Kunio NAKATA, Kazutaka SHIMBO, Yutaka MARUYAMA, Yayoi KAWATO
-
Patent number: 9174932Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.Type: GrantFiled: March 28, 2014Date of Patent: November 3, 2015Assignee: AJINOMOTO CO., INC.Inventors: Masayuki Sugiki, Toru Okamatsu, Sayaka Asari, Yayoi Kawato, Toshihiro Hatanaka, Tetsuo Yano, Yukie Seki, Naohiro Miyamura, Hiroaki Nagasaki, Yuzuru Eto, Reiko Yasuda
-
Publication number: 20140303122Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 28, 2014Publication date: October 9, 2014Applicant: AJINOMOTO CO., INC.Inventors: Masayuki SUGIKI, Toru Okamatsu, Sayaka Asari, Yayoi Kawato, Toshihiro Hatanaka, Tetsuo Yano, Yukie Seki, Naohiro Miyamura, Hiroaki Nagasaki, Yuzuru Eto, Reiko Yasuda
-
Patent number: 8796485Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 4, 2011Date of Patent: August 5, 2014Assignee: Ajinomoto Co., Inc.Inventors: Masayuki Sugiki, Toru Okamatsu, Sayaka Asari, Yayoi Kawato, Toshihiro Hatanaka, Tetsuo Yano, Yukie Seki, Naohiro Miyamura, Hiroaki Nagasaki, Yuzuru Eto, Reiko Yasuda
-
Publication number: 20120088737Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 12, 2012Applicant: AJINOMOTO CO., INCInventors: Wataru MIYANAGA, Yoichiro SHIMA, Misato NOGUCHI, Akiko OONUKI, Yayoi KAWATO, Hiroshi IWATA, Eri HARADA, Ryuta TAKASHITA, Hirokazu UENO, Tadakiyo NAKAGAWA
-
Publication number: 20110251418Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 4, 2011Publication date: October 13, 2011Applicant: AJINOMOTO CO., INC.Inventors: Masayuki Sugiki, Toru Okamatsu, Sayaka Asari, Yayoi Kawato, Toshihiro Hatanaka, Tetsuo Yano, Yukie Seki, Naohiro Miyamura, Hiroaki Nagasaki, Yuzuru Eto, Reiko Yasuda
-
Patent number: 7994353Abstract: The present invention provides PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.Type: GrantFiled: March 5, 2009Date of Patent: August 9, 2011Assignee: Ajinomoto Co., Inc.Inventors: Akiko Oonuki, Toshihiko Yoshimura, Katsumi Maezono, Yayoi Kawato, Hideyuki Tanaka, Naoyuki Fukuchi, Nozomu Ishida
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Patent number: 7732637Abstract: The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient.Type: GrantFiled: August 7, 2007Date of Patent: June 8, 2010Assignee: Ajinomoto Co., Inc.Inventors: Katsumi Maezono, Toshihiko Yoshimura, Nozomu Ishida, Naoyuki Fukuchi, Toshihiro Hatanaka, Osamu Ikehara, Yayoi Kawato, Hideyuki Tanaka
-
Patent number: 7728158Abstract: The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.Type: GrantFiled: May 25, 2007Date of Patent: June 1, 2010Assignee: Ajinomoto Co., Inc.Inventors: Akiko Oonuki, Toshihiko Yoshimura, Katsumi Maezono, Yayoi Kawato, Hideyuki Tanaka, Naoyuki Fukuchi, Nozomu Ishida
-
Publication number: 20100063151Abstract: The present invention provides acylamide compounds, prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, and therapeutic methods by administering the same.Type: ApplicationFiled: November 18, 2009Publication date: March 11, 2010Applicant: Ajinomoto Co., Inc.Inventors: Katsumi MAEZONO, Toshihiko YOSHIMURA, Nozomu ISHIDA, Naoyuki FUKUCHI, Toshihiro HATANAKA, Osamu IKEHARA, Yayoi KAWATO, Hideyuki TANAKA
-
Publication number: 20090259061Abstract: The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 5, 2009Publication date: October 15, 2009Applicant: AJINOMOTO, CO., INC.Inventors: Akiko OONUKI, Toshihiko YOSHIMURA, Katsumi MAEZONO, Yayoi KAWATO, Hideyuki TANAKA, Naoyuki FUKUCHI, Nozomu ISHIDA
-
Publication number: 20070282002Abstract: The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient.Type: ApplicationFiled: August 7, 2007Publication date: December 6, 2007Applicant: AJINOMOTO CO. INCInventors: Katsumi MAEZONO, Toshihiko Yoshimura, Nozomu Ishida, Naoyuki Fukuchi, Toshihiro Hatanaka, Osamu Ikehara, Yayoi Kawato, Hideyuki Tanaka
-
Publication number: 20070276041Abstract: The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 25, 2007Publication date: November 29, 2007Applicant: AJINOMOTO, CO., INC.Inventors: Akiko Oonuki, Toshihiko Yoshimura, Katsumi Maezono, Yayoi Kawato, Hideyuki Tanaka, Naoyuki Fukuchi, Nozomu Ishida